Athena Kartsaklis - VBI Vaccines President

VBIV Stock  USD 0.58  0.01  1.75%   

President

Ms. Athena Kartsaklis is Senior Vice President Finance, Principal Accounting Officer, Chief Compliance Officer, Controller of the Company. She is a Canadian chartered professional accountant and U.S. certified public accountant and has over 25 years of experience in conducting audits and managing financial reporting and reviewing internal controls. Before joining the Company as corporate controller in May 2017, Ms. Kartsaklis served as a senior vice president of SkyWave Mobile Communications Inc. since December 2013, managing financial reporting, budget and forecast process and audit and other accounting matters. Ms. Kartsaklis was the manager, financial reporting at Alterna Savings, Ottawa, Canada, from September 2012, mainly responsible for financial and administrative reporting. From 1992 to September 2012, Ms. Kartsaklis worked at Deloitte, Hadjipavlou, Sofianos Cambanis S.A., Athens Greece, and became a partner in 2000, overseeing and performing audits and advising clients on audit and accounting matters since 2018.
Age 59
Tenure 6 years
Address 160 Second Street, Cambridge, MA, United States, 02142
Phone617 830 3031
Webhttps://www.vbivaccines.com
Kartsaklis received a bachelor of commerce degree from Dalhousie University in Halifax, Nova Scotia.

VBI Vaccines Management Efficiency

The company has return on total asset (ROA) of (0.295) % which means that it has lost $0.295 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1979) %, meaning that it created substantial loss on money invested by shareholders. VBI Vaccines' management efficiency ratios could be used to measure how well VBI Vaccines manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to climb to -0.76 in 2024. Return On Assets is likely to drop to -0.86 in 2024. At this time, VBI Vaccines' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 93.5 M in 2024, whereas Intangible Assets are likely to drop slightly above 48.2 M in 2024.
The company currently holds 52.23 M in liabilities with Debt to Equity (D/E) ratio of 0.32, which is about average as compared to similar companies. VBI Vaccines has a current ratio of 2.24, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist VBI Vaccines until it has trouble settling it off, either with new capital or with free cash flow. So, VBI Vaccines' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like VBI Vaccines sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for VBI to invest in growth at high rates of return. When we think about VBI Vaccines' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

PRESIDENT Age

Bruce CFAEquillium
58
Craig PhilipsKineta Inc
63
Patrick KaltenbachAgilent Technologies
53
Mark DoakAgilent Technologies
63
Samraat RahaAgilent Technologies
51
Henrik AncherJensenAgilent Technologies
59
Jacob ThaysenAgilent Technologies
49
Michael TangAgilent Technologies
50
Rodney GonsalvesAgilent Technologies
58
Eilon AsculaiMediwound
N/A
Dominique GrauAgilent Technologies
65
Alicia RodriguezAgilent Technologies
N/A
Bruce SteelEquillium
50
Robert McMahonAgilent Technologies
55
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts. Vbi Vaccines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people. VBI Vaccines (VBIV) is traded on NASDAQ Exchange in USA. It is located in 160 Second Street, Cambridge, MA, United States, 02142 and employs 190 people. VBI Vaccines is listed under Biotechnology category by Fama And French industry classification.

Management Performance

VBI Vaccines Leadership Team

Elected by the shareholders, the VBI Vaccines' board of directors comprises two types of representatives: VBI Vaccines inside directors who are chosen from within the company, and outside directors, selected externally and held independent of VBI. The board's role is to monitor VBI Vaccines' management team and ensure that shareholders' interests are well served. VBI Vaccines' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, VBI Vaccines' outside directors are responsible for providing unbiased perspectives on the board's policies.
Adam Buckley, Vice President - Operations and Project Management
Nicole Anderson, Director Relations
David Anderson, Chief Scientific Officer
Trent Davis, Director
Shayla Forster, Corporate Secretary
Joanne Cordeiro, Director
Sam Chawla, Director
Alan Timmins, Independent Director
Avi Mazaltov, Global SciVac
Misha Nossov, Senior Europe
Marc Kirchmeier, VP of Formulations
Curtis Lockshin, CEO, Director
David Rector, Additional Independent Director
Dmitry Genkin, Director
Michel Wilde, Independent Director
Kate Inman, Director
Ran Nussbaum, Director
FRCPC MD, Chief Officer
Tomer Kariv, Director
Adam Logal, Director
Steven Gillis, Independent Chairman of the Board
Steven Rubin, Chairman of the Board
Jeff Baxter, CEO, Director
Nell Beattie, Chief Officer
Athena Kartsaklis, Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller
James Martin, CFO
FCMA FCMA, CEO Pres
Christopher McNulty, CFO and Head of Business Development
Jeffery FCMA, CEO President
Scott Requadt, Independent Director
Egidio Nascimento, CFO
John Dillman, Chief Officer

VBI Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is VBI Vaccines a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether VBI Vaccines is a strong investment it is important to analyze VBI Vaccines' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact VBI Vaccines' future performance. For an informed investment choice regarding VBI Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in VBI Vaccines. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy VBI Stock please use our How to Invest in VBI Vaccines guide.
You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for VBI Stock analysis

When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
AI Investment Finder
Use AI to screen and filter profitable investment opportunities
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Transaction History
View history of all your transactions and understand their impact on performance
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Is VBI Vaccines' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VBI Vaccines. If investors know VBI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VBI Vaccines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(9.79)
Revenue Per Share
0.689
Quarterly Revenue Growth
19.896
Return On Assets
(0.29)
Return On Equity
(2.20)
The market value of VBI Vaccines is measured differently than its book value, which is the value of VBI that is recorded on the company's balance sheet. Investors also form their own opinion of VBI Vaccines' value that differs from its market value or its book value, called intrinsic value, which is VBI Vaccines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VBI Vaccines' market value can be influenced by many factors that don't directly affect VBI Vaccines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VBI Vaccines' value and its price as these two are different measures arrived at by different means. Investors typically determine if VBI Vaccines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VBI Vaccines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.